Alector, Inc. (ALEC) NASDAQ
1.95
-0.125(-6.04%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.95
-0.125(-6.04%)
Currency In USD
| Previous Close | 2.07 |
| Open | 2.07 |
| Day High | 2.07 |
| Day Low | 1.92 |
| 52-Week High | 3.4 |
| 52-Week Low | 1.09 |
| Volume | 1.1M |
| Average Volume | 671,604 |
| Market Cap | 215.94M |
| PE | -1.63 |
| EPS | -1.19 |
| Moving Average 50 Days | 2.3 |
| Moving Average 200 Days | 2.12 |
| Change | -0.13 |
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
GlobeNewswire Inc.
Dec 12, 2025 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that
Alector to Participate in the Bank of America CNS Therapeutics Conference
GlobeNewswire Inc.
Dec 01, 2025 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that